NAVB Share Price

Open 0.75 Change Price %
High 0.75 1 Day -0.01 -1.35
Low 0.72 1 Week 0.01 1.39
Close 0.73 1 Month -0.12 -14.12
Volume 469344 1 Year -0.72 -49.66
52 Week High 1.51
52 Week Low 0.26
NAVB Important Levels
Resistance 2 0.76
Resistance 1 0.75
Pivot 0.73
Support 1 0.71
Support 2 0.70
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
NGD 3.93 5.65%
NGD 3.93 5.65%
NAK 1.52 7.04%
NAK 1.52 7.04%
PBTH 8.23 0.37%
PLX 0.30 -9.09%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
CHGS 0.00 -100.00%
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
SIF 8.65 -18.40%
More..

Navidea Biopharmaceuticals, Inc. (AMEX: NAVB)

NAVB Technical Analysis 4
As on 7th Dec 2016 NAVB Share Price closed @ 0.73 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.85 & Strong Sell for SHORT-TERM with Stoploss of 0.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
NAVB Target for December
1st Target up-side 1.01
2nd Target up-side 1.17
3rd Target up-side 1.33
1st Target down-side 0.57
2nd Target down-side 0.41
3rd Target down-side 0.25
NAVB Other Details
Segment EQ
Market Capital 274868832.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.navidea.com
NAVB Address
NAVB
5600 Blazer Parkway
Suite 200
Dublin, OH 43017
United States
Phone: 614-793-7500
Fax: 614-793-7522
NAVB Latest News
Interactive Technical Analysis Chart Navidea Biopharmaceuticals, Inc. ( NAVB AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Navidea Biopharmaceuticals, Inc.
NAVB Business Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.